About cervical cancer
Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world's fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells. Cervical cancer is caused due to the infection of HPV. There are no signs and symptoms to identify the early stages of cervical cancer, but it can be identified through regular check-ups. Vaginal bleeding and pelvic pain are usually observed as signs and symptoms of cervical cancer. Before cancer detected in the cervix, cervix cells go through changes, called as dysplasia, in which abnormal cells start to expose in the cervical tissue. Over a period, the abnormal cells may developed into cancer cells and begin to grow and spread more deeply into the cervix and surrounding areas.
Technavio's analysts forecast the global cervical cancer market to grow at a CAGR of 4.87% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the global cervical cancer market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment and prevention of cervical cancer.
Technavio's report, Global Cervical Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cervical cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
Americas
APAC
EMEA
Key vendors
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Other prominent vendors
Advaxis Immunotherapies
Bionor Pharma
Dendreon Corporation
Inovio Pharmaceuticals
ISA Pharmaceuticals
Otsuka Pharmaceuticals
Profectus Biosciences
Virometix
Zeria Pharmaceuticals
Key market driver
Increase in incidence rate
For a full, detailed list, view our report
Key market challenge
Adverse effects of drugs and vaccines
For a full, detailed list, view our report
Key market trend
Patient assistance programs
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Risk factors
Signs and symptoms
Screening
Diagnosis
Staging
Treatment
Epidemiology
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Market segmentation by application
Global prophylactic vaccines market
Global therapeutic drugs market
PART 08: Market segmentation by type of therapy
Global cervical cancer therapeutics market by type of therapy
Chemotherapy
Targeted therapy
HPV vaccines
PART 09: Geographical segmentation
PART 10: Key brand analysis
Comparative study between Gardasil, Gardasil 9, and Cervarix
PART 11: Pipeline portfolio
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
Competitive scenario
Market analysis 2014
Other prominent vendors
PART 18: Key vendor analysis
GSK
F. Hoffmann-La Roche
Merck
PART 19: Appendix
List of abbreviations
PART 20: Explore Technavio
List of Exhibits
Exhibit 01: Risk factors for cervical cancer
Exhibit 02: Screening tests for cervical cancer
Exhibit 03: Diagnostic tests for cervical cancer
Exhibit 04: FIGO staging for cervical cancer
Exhibit 05: Management of cervical cancer
Exhibit 06: Chemotherapy for treatment of cervical cancer
Exhibit 07: Cervical cancer treatment algorithm
Exhibit 08: Countries with highest cervical cancer rates
Exhibit 09: Cervical cancer deaths by age group in the US 2008-2012
Exhibit 10: Age-specific incidence rates of cervical cancer in the US by race 2008-2012
Exhibit 11: Age-specific mortality rates of cervical cancer of women in the US by race 2008-2012
Exhibit 12: Mortality rates of cervical cancer of women in the US by race 2008-2012
Exhibit 13: Average number of cervical cancer deaths in EU 2010-2012
Exhibit 14: Cervical cancer incidence and mortality rates in EU 2007-2011
Exhibit 15: Global cervical cancer therapeutics market 2014-2019 ($ billions)
Exhibit 16: Global cervical cancer therapeutics market segmentation by application
Exhibit 17: Global prophylactic vaccines market 2014-2019 ($ millions)
Exhibit 18: Global therapeutic drugs market 2014-2019 ($ millions)
Exhibit 19: Segmentation of global cervical cancer therapeutics market 2014
Exhibit 20: Global cervical cancer therapeutics market by type of therapy
Exhibit 21: Segmentation of global cervical cancer therapeutics market by region 2014
Exhibit 22: Global cervical cancer vaccines market: Comparison of major brands
Exhibit 23: Gardasil, Gardasil 9, and Cervarix: A comparative study
Exhibit 24: Key late-stage HPV vaccines for cervical cancer
Exhibit 25: Drivers of global cervical cancer therapeutics market
Exhibit 26: Impact of drivers
Exhibit 27: Challenges of global cervical cancer therapeutics market
Exhibit 28: Impact of drivers and challenges
Exhibit 29: Trends of global cervical cancer therapeutics market
Exhibit 30: Gardasil: Global revenue and growth rate 2011-2014
Exhibit 31: Merck: Key takeaways
Exhibit 32: Cervarix: Global revenue and growth rate 2012-2014
Exhibit 33: GSK: Key takeaways
Exhibit 34: F. Hoffman-La Roche: Key takeaways
